U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H14NO.Br
Molecular Weight 220.107
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FURTRETHONIUM BROMIDE

SMILES

[Br-].C[N+](C)(C)CC1=CC=CO1

InChI

InChIKey=BXGSZEWYYLFSEJ-UHFFFAOYSA-M
InChI=1S/C8H14NO.BrH/c1-9(2,3)7-8-5-4-6-10-8;/h4-6H,7H2,1-3H3;1H/q+1;/p-1

HIDE SMILES / InChI
Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C8H14NO
Molecular Weight 140.2029
Charge 1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

FURTRETHONIUM is an agonist of muscarinic acetylcholine receptors. It was used for the treatment of glaucoma.

Approval Year

1944
15
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Furmethide

Approved Use

Furtrethonum is a parasympathomimetic drug used for the treatment of glaucoma
Doses

Doses

DosePopulationAdverse events​
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14829485
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/14829485
Disc. AE: Dacryostenosis acquired...
AEs leading to
discontinuation/dose reduction:
Dacryostenosis acquired (71%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14829485
AEs

AEs

AESignificanceDosePopulation
Dacryostenosis acquired 71%
Disc. AE
10 % 1 times / day multiple, ophthalmic
Dose: 10 %, 1 times / day
Route: ophthalmic
Route: multiple
Dose: 10 %, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14829485
unhealthy
n = 21
Health Status: unhealthy
Condition: glaucoma
Population Size: 21
Sources:
https://pubmed.ncbi.nlm.nih.gov/14829485
Sourcing

Sourcing

Vendor/AggregatorIDURL
ABI Chem
AC1L1W9Q
BOC Sciences
541-64-0
ChemMol
99154117
http://www.chemmol.com/chemmol/99154117.html
Enamine
BBV-82745797
Enamine
EN300-1588178
MolPort
MolPort-006-111-713
NCI Plated 2007
27126
NCI Plated 2007
44407
NovoSeek
10938
ZINC
ZINC000000001500
http://zinc15.docking.org/substances/ZINC000000001500
eMolecules
109817126
PubMed

PubMed

TitleDatePubMed
The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma.
1947 Aug
Patents

Patents

JP2002105045A
7
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:26:12 GMT 2023
Edited
by admin
on Sat Dec 16 11:26:12 GMT 2023
Record UNII
L22EQ82EJ0
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FURTRETHONIUM BROMIDE
Common Name English
FURFURYLTRIMETHYLAMMONIUM BROMIDE
Systematic Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, BROMIDE
Systematic Name English
2-FURANMETHANAMINIUM, N,N,N-TRIMETHYL-, BROMIDE (1:1)
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID80994478
Created by admin on Sat Dec 16 11:26:12 GMT 2023 , Edited by admin on Sat Dec 16 11:26:12 GMT 2023
PRIMARY
FDA UNII
L22EQ82EJ0
Created by admin on Sat Dec 16 11:26:12 GMT 2023 , Edited by admin on Sat Dec 16 11:26:12 GMT 2023
PRIMARY
PUBCHEM
52039
Created by admin on Sat Dec 16 11:26:12 GMT 2023 , Edited by admin on Sat Dec 16 11:26:12 GMT 2023
PRIMARY
CAS
73664-18-3
Created by admin on Sat Dec 16 11:26:12 GMT 2023 , Edited by admin on Sat Dec 16 11:26:12 GMT 2023
PRIMARY
Related Record Type Details
Structure of FURTRETHONIUM
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of FURTRETHONIUM
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966